StoneX Group Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 43.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 76,031 shares of the biopharmaceutical company's stock after buying an additional 23,050 shares during the period. StoneX Group Inc.'s holdings in Pfizer were worth $2,017,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
PFE has been the topic of a number of research reports. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Bank of America reiterated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $31.92.
Read Our Latest Report on Pfizer
Insider Activity at Pfizer
In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.
Pfizer Trading Down 1.6 %
NYSE PFE traded down $0.41 on Thursday, reaching $24.30. The stock had a trading volume of 53,412,700 shares, compared to its average volume of 39,300,419. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $137.79 billion, a price-to-earnings ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.26 and a 12-month high of $31.54. The stock has a fifty day moving average price of $25.98 and a two-hundred day moving average price of $26.83.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 EPS. The firm's revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
